SynAct Pharma is weeks away from one of the most anticipated clinical readouts in its history. The Phase 2b ADVANCE study – 246 newly diagnosed rheumatoid arthritis patients, 12 weeks of treatment, three dose levels – has completed recruitment and is expected to deliver topline data in Q2 2026. This is the year that will define whether selective melanocortin agonism can establish itself as a genuine therapeutic class. But what does a positive result actually look like, and how should investors interpret the data when it arrives? BioStock put those questions directly to Chief Business Officer Mads Bjerregaard.

Read the full interview at biostock.se: What good data looks like: SynAct Pharma ahead of its ADVANCE readout

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStockStay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter Follow BioStock on social media: LinkedIn and Facebook! About BioStock BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments. BioStock – Connecting Innovation & Capital.